Coronaviruses (CoVs) act as cross-species viruses and have the potential to spread rapidly 31 into new host species and cause epidemic diseases. Despite the severe public health threat of 32 severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome CoV 33 (MERS-CoV), there are currently no drugs available for their treatment; therefore, 34 broad-spectrum inhibitors of emerging and endemic CoVs are urgently needed. To search for 35 effective inhibitory agents, we performed high-throughput screening (HTS) of a 36 2,000-compound library of approved drugs and pharmacologically active compounds using 37 the established genetically engineered human CoV OC43 (HCoV-OC43) strain expressing 38 Renilla luciferase (rOC43-ns2Del-Rluc) and validated the inhibitors using multiple 39 genetically distinct CoVs in vitro. We screened 56 hits from the HTS data and validated 36 40 compounds in vitro using wild-type HCoV-OC43. Furthermore, we identified seven 41 compounds (lycorine, emetine, monensin sodium, mycophenolate mofeti, mycophenolic acid, 42 phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to their 43 strong inhibition of replication by four CoVs in vitro at low-micromolar concentrations.
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. Interestingly, the following seven compounds inhibited the replication of all CoVs 149 with EC 50 < 5 μM: lycorine, emetine, phenazopyridine, mycophenolic acid, mycophenolate 150 mofetil, pyrvinium pamoate, and monensin sodium (Table 1; bold) . 151 These seven broad-spectrum inhibitors suppressed the replication of all CoVs in a 152 dose-dependent manner and with low EC 50 values (Figure 2) . Lycorine, an active alkaloid 153 from the common folk medicine Lycoris radiata (Amaryllidaceae) has been investigated for 154 its multifunctional biological effects, including anticancer, antimalarial, antiviral, 155 antibacterial, and anti-inflammatory activities (19) (20) (21) (22) (23) . Lycorine showed potent anti-CoV 156 activity, with EC 50 values ranging from 0.15 μM to 1.63 μM. Moreover, the selective index 157 (SI) of lycorine for HCoV-OC43 was calculated at 29.13, indicating its potent 158 anti-HCoV-OC43 activity (Figure 2A ). Emetine is an active principal of ipecac and inhibits 159 the replication of both DNA and RNA viruses. Additionally, emetine displayed potent 160 anti-CoV activity and the strongest anti-MERS-CoV activity among the top seven inhibitors, 161 with an EC 50 value of 0.34 μM and SI of 9.06 ( Figure 2B ). Mycophenolic acid (an 162 immunosuppressant) exerted a significant inhibitory effect on HCoV-OC43 replication, with 163 an EC 50 of 1.95 μM, and showed stronger anti-HCoV-NL63 activity than the others (EC 50 = 164 0.18 μM and SI = 19.11) ( Figure 2E ). Mycophenolate mofetil, a derivative of mycophenolic 165 acid, showed a similar antiviral effect on the four CoVs as that from mycophenolic acid, 166 suggesting that the two drugs might harbor similar core structures and antiviral mechanisms 167 ( Figure 2C and E). Moreover, phenazopyridine, a widely used urinary analgesic, also 168 displayed strong broad-spectrum anti-CoV activity for the first time, especially against Therefore, we used this model to evaluate the in vivo antiviral activity of the seven inhibitors.
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Intracerebral or intranasal inoculation of HCoV-OC43 results in acute-onset severe 205 neurological illness and causes death, with high levels of viral replication in the brain [titer > 206 10 6 50% tissue culture infective dose (TCID 50 )/mL] at 3 to 5 days after infection (26-29).
207
Briefly, female BALB/c mice (12-days old) were inoculated via the intranasal route with 100 208 TCID 50 of HCoV-OC43-WT and treated with the seven inhibitors for 14 days, and their 209 survival was monitored for up to 20 days. The inhibitor doses and regimens were selected 210 based on acute-toxicity assessments. Emetine was used at 5 mg/kg, and chloroquine was used 211 as the positive control, which showed antiviral activity at 30 mg/kg. All mice in the 212 phosphate-buffered saline (PBS)/DMSO-treated group died within 6 days after group were still alive at 20-days post-inoculation (p < 0.001), similar to the survival rate of 215 the chloroquine-treated group ( Figure 5A ). Additionally, viral loads in the brain and spinal 216 cord were under the limit of detection in the lycorine-treated group ( Figure 5B ), and 217 immunohistochemistry (IHC) of mouse-brain coronal sections showed that HCoV-OC43 218 nucleocapsid protein was present only in the PBS/DMSO-treated group but not in the 219 lycorine-treated group ( Figure 5C ). Figure 6A ). These observations were confirmed by the 228 ~2 × 10 5 -fold higher Rluc activity in the PBS/DMSO-treated mice than in the lycorine-treated 229 mice. Therefore, lycorine showed promise as an anti-CoV agent ( Figure 6B ). The criteria for the inhibition rate associated with the signals in the antiviral HTS 255 screening assay ranged from ~30% to ~90% according to different references, with more 256 primary hits but fewer efficacy hits screened when the inhibition rate was set to the lower 257 threshold. In our experiment, we focused on screening hits with higher potency; therefore, so 13 established the inhibition threshold at 70%. Furthermore, we identified several effective hits 259 with a high degree of cytotoxicity under 10 μM in our primary screening, which was why the 260 cytotoxicity value was set to 80%. Finally, we identified 36 compounds exhibiting Lycorine also exhibits strong activities against influenza A virus H5H1 in vitro and delays the 281 export of nucleoprotein from the nucleus to the cytoplasm during replication (52). However, 282 the potential mechanism of lycorine against CoVs requires further exploration, and its 283 potential selection for drug-resistant strains must be assessed. We found no reports 284 concerning whether its use in combination enhances the antiviral efficacy of lycorine. (Table S1 ).
340
The anti-HCoV-OC43 nucleocapsid protein mouse monoclonal antibody was made Valencia, CA, USA) and quantified by real-time RT-PCR, as described previously (64, 65).
350
The primer and probe sequences were as follows: q-OC43-F, 5-GCT CAG GAA GGT CTG Figure 1A) . After incubation for 60 min, assessment of the quality of screening assays, was determined, and compounds were 383 considered effective if they reduced Rluc activity by ≥ 70% and cytotoxicity by ≤ 80%.
384
A confirmation assay was performed using HCoV-OC43-WT treated with the 385 compounds at two concentrations (10 and 5 μM), and viral RNA load was determined by 386 qRT-PCR. To screen hits with higher potency and narrow the screening scope, a compound 387 was considered effective only if the EC 50 value was <5 μM. 
